The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | CLL highlights from ASCO & EHA 2025: SEQUOIA, FLAIR, & CAPTIVATE trials
In this video, Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, shares her highlights in chronic lymphocytic leukemia (CLL) from the 2025 ASCO and EHA meetings, outlining some trials of interest that were updated at these events. This includes the SEQUOIA trial (NCT03336333), FLAIR trial (ISRCTN01844152), and the long-term follow-up of the CAPTIVATE study (NCT02910583). This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I wasn’t attending ASCO, but based on the main data that were presented, we now know that also the combination of zanubrutinib plus venetoclax in the SEQUOIA trial is effective and can achieve different responses and long-lasting disease control, though this is a combination that is not exactly administered in a fixed duration way in the RMD of the trial because treatment was tailored according to the MRD levels and the iwCLL response criteria...
I wasn’t attending ASCO, but based on the main data that were presented, we now know that also the combination of zanubrutinib plus venetoclax in the SEQUOIA trial is effective and can achieve different responses and long-lasting disease control, though this is a combination that is not exactly administered in a fixed duration way in the RMD of the trial because treatment was tailored according to the MRD levels and the iwCLL response criteria.
In terms of the EHA novel data, there is the update of the FLAIR trial that is a very interesting and very smart trial. And now we know, thanks to this update, that the combination of Ibrutinib plus Venetoclax is even more effective than Ibrutinib alone in terms of improving progression-free survival and overall survival of patients treated in first line. So this is very exciting news.
And together with the update of the FLAIR trial as I mentioned, the long-term follow-up of the CAPTIVATE study is very interesting because we are gathering more data on durability of responses and up to 66 percent of patients are still progression-free in the fixed duration cohort after 5.5 years and when they progress we now know that we can retreat them with either Ibrutinib alone or Ibrutinib plus Venetoclax and in more than 80 percent of cases we achieve responses so that’s again very good news for patients and physicians taking care of patients with CLL.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
